A new clock that analyzes the age of the immune system may be the next big thing in aging biomarkers.

Measuring the age of your immune system

As we age, our immune systems begin to decline due to many factors, including the thymus shrinking and producing ever-fewer T cells, the ever-increasing chronic inflammation called “inflammaging”, dysfunctional immune cells doing more harm than good, and a lifetime of microbial burden taking its toll. This gradual decline of the immune system is known as immunosenescence.

The efficient function of the immune system is known to be a determinant of longevity, and the immunological model of cancer shows that it plays a central role in your risk of developing cancer.

This is no surprise, considering the many functions that the immune system performs and all of the cell types that perform them. From repelling invading pathogens and facilitating wound healing to clearing away cellular garbage, the immune system is the workhorse of the body and essential to life.

In a new study, researchers have published the details of a new aging clock that measures how well the immune system is working. It could be a valuable tool for interventions that target the aging processes in order to prevent age-related diseases [1].

It is currently a challenge to accurately ascertain the state of an individual’s immune system, but these researchers claim that IMM-AGE can be used to analyze the immune system to give an accurate prediction of disease risk and life expectancy.

IMM-AGE is a biological clock that may help track the immune decline that occurs in old age, which is known as immunosenescence. The research team believes that it could provide an “immune age” and be used alongside chronological age to help inform healthcare and drug development.


Immune responses generally decline with age. However, the dynamics of this process at the individual level have not been characterized, hindering quantification of an individual’s immune age. Here, we use multiple ‘omics’ technologies to capture population- and individual-level changes in the human immune system of 135 healthy adult individuals of different ages sampled longitudinally over a nine-year period. We observed high inter-individual variability in the rates of change of cellular frequencies that was dictated by their baseline values, allowing identification of steady-state levels toward which a cell subset converged and the ordered convergence of multiple cell subsets toward an older adult homeostasis. These data form a high-dimensional trajectory of immune aging (IMM-AGE) that describes a person’s immune status better than chronological age. We show that the IMM-AGE score predicted all-cause mortality beyond well-established risk factors in the Framingham Heart Study, establishing its potential use in clinics for identification of patients at risk.


If this new clock proves reliable, it could take its place alongside the gold standard for aging biomarkers, the epigenetic clock, along with the newer ribosomal clock. It may prove useful in the development of drugs and vaccines as well as clinical trials in which the aging processes are the focus of therapies. There is certainly a need for more aging biomarkers, so this could potentially be added to the toolkit to help our industry develop therapies.


More News


[1] Alpert, A., Pickman, Y., Leipold, M., Rosenberg-Hasson, Y., Ji, X., Gaujoux, R., … & Furman, D. (2019). A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nature Medicine, 1.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
  1. March 30, 2019

    Good information. Lucky me I came across your website by chance
    (stumbleupon). I’ve saved as a favorite for later!

Write a comment:


Your email address will not be published.

Privacy Policy / Terms Of Use

       Powered by MMD